TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis: Randomized Controlled Trial
Brief Summary: The objective of this study is to determine for previously healthy children who present to a Canadian Emergency Department (ED) with acute gastroenteritis (infection or irritation of the digestive tract); if compared with placebo, the administration of a probiotic agent (Lacidofil) will result in a significantly lower proportion of children developing moderate to severe disease over the subsequent 2 weeks and will not be associated with a significantly greater occurrence of side effects.


Options:
A: Intervention Type: DRUG; Name: Biothree; Assigned to Arm(s): N/A
B: Arm Label: Lacidofil; Type: EXPERIMENTAL; Interventions: Drug: Lacidofil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lacidofil; Assigned to Arm(s): Lacidofil
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: GB (Florestor) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: GRALB | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: GC (placebo) | Intervention Type: DRUG; Name: GB (Florestor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: GRALB; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GC (placebo); Assigned to Arm(s): 3
D: Arm Label: LGG; Type: EXPERIMENTAL; Interventions: Drug: LGG | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: micro-crystalline cellulose | Intervention Type: DRUG; Name: LGG; Assigned to Arm(s): LGG | Intervention Type: DRUG; Name: micro-crystalline cellulose; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU)
Brief Summary: This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA).

This research is being done to compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure over the 12-week treatment period. Vehicle looks the same as HP802-247 but contains no cells.

At least 440 subjects will participate. The study is going to be conducted in approximately 5 countries at approximately 50 sites across the European Union.


Options:
A: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP-802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP-802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle
B: Arm Label: becaplermin gel; Type: EXPERIMENTAL; Interventions: Drug: becaplermin gel | Arm Label: Duoderm Hydrogel™; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duoderm Hydrogel™ | Intervention Type: DRUG; Name: becaplermin gel; Assigned to Arm(s): becaplermin gel | Intervention Type: DRUG; Name: Duoderm Hydrogel™; Assigned to Arm(s): Duoderm Hydrogel™
C: Arm Label: Keratin dressings; Type: EXPERIMENTAL; Interventions: Device: Keratin dressings | Arm Label: Usual care dressings; Type: ACTIVE_COMPARATOR; Interventions: Device: Usual care dressings | Intervention Type: DEVICE; Name: Keratin dressings; Assigned to Arm(s): Keratin dressings | Intervention Type: DEVICE; Name: Usual care dressings; Assigned to Arm(s): Usual care dressings
D: Arm Label: HP802-247 plus compression therapy; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: HP802-247 Vehicle plus compression therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: HP802-247 Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 plus compression therapy | Intervention Type: OTHER; Name: HP802-247 Vehicle; Assigned to Arm(s): HP802-247 Vehicle plus compression therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Physical Activity in Patients With Severe Chronic Obstructive Pulmonary Disease With Urban Walking Circuits
Brief Summary: The aim of this study was to assess the effectiveness of the implementation of walking urban circuits in increasing the level of physical activity and exercise capacity in severe chronic obstructive pulmonary disease (COPD) patients after being enrolled in a pulmonary rehabilitation program.


Options:
A: Arm Label: rehabilitation program more the urban circuit; Type: EXPERIMENTAL; Interventions: Other: rehabilitation more the urban circuit | Arm Label: rehabilitation program non circuit group .; Type: EXPERIMENTAL; Interventions: Other: rehabilitation program but not given urbane circuits | Intervention Type: OTHER; Name: rehabilitation more the urban circuit; Assigned to Arm(s): rehabilitation program more the urban circuit | Intervention Type: OTHER; Name: rehabilitation program but not given urbane circuits; Assigned to Arm(s): rehabilitation program non circuit group .
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tiotropium; Type: EXPERIMENTAL; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Inspiratory Muscle Training; Type: EXPERIMENTAL; Interventions: Procedure: Inspiratory Muscle Training | Arm Label: Sham IMT; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Inspiratory Muscle Training | Intervention Type: PROCEDURE; Name: Inspiratory Muscle Training; Assigned to Arm(s): Inspiratory Muscle Training, Sham IMT
D: Arm Label: Aclidinium bromide; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Physical Activity in Patients With Severe Chronic Obstructive Pulmonary Disease With Urban Walking Circuits
Brief Summary: The aim of this study was to assess the effectiveness of the implementation of walking urban circuits in increasing the level of physical activity and exercise capacity in severe chronic obstructive pulmonary disease (COPD) patients after being enrolled in a pulmonary rehabilitation program.


Options:
A: Arm Label: rehabilitation program more the urban circuit; Type: EXPERIMENTAL; Interventions: Other: rehabilitation more the urban circuit | Arm Label: rehabilitation program non circuit group .; Type: EXPERIMENTAL; Interventions: Other: rehabilitation program but not given urbane circuits | Intervention Type: OTHER; Name: rehabilitation more the urban circuit; Assigned to Arm(s): rehabilitation program more the urban circuit | Intervention Type: OTHER; Name: rehabilitation program but not given urbane circuits; Assigned to Arm(s): rehabilitation program non circuit group .
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pulmonary rehabilitation (PR) | Intervention Type: BEHAVIORAL; Name: Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer; Assigned to Arm(s): Experimental group | Intervention Type: BEHAVIORAL; Name: Pulmonary rehabilitation (PR); Assigned to Arm(s): Control group
C: Arm Label: Telemedicine (TeleRR); Type: EXPERIMENTAL; Interventions: Device: Telemedicine: Maintenance Respiratory Rehabilitation | Arm Label: Clinical Practice (Recommendation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine: Maintenance Respiratory Rehabilitation; Assigned to Arm(s): Telemedicine (TeleRR)
D: Arm Label: Device: KAIA COPD-App (Medical Mobile Application).; Type: EXPERIMENTAL; Interventions: Device: Kaia COPD Application | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Kaia COPD Application; Assigned to Arm(s): Device: KAIA COPD-App (Medical Mobile Application). | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo
Brief Summary: This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose inhaler (MDI) (GFF; PT003), GP MDI (PT001), and FF MDI (PT005) compared with Placebo MDI in subjects with moderate to very severe COPD.


Options:
A: Arm Label: FF MDI (PT005); Type: EXPERIMENTAL; Interventions: Drug: FF MDI (PT005) | Arm Label: GP MDI (PT001); Type: EXPERIMENTAL; Interventions: Drug: GP MDI (PT001) | Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) | Arm Label: Placebo MDI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GFF MDI (PT003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: GP MDI (PT001); Assigned to Arm(s): GP MDI (PT001) | Intervention Type: DRUG; Name: FF MDI (PT005); Assigned to Arm(s): FF MDI (PT005) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI
B: Arm Label: indacaterol/glycopyrrolate 300/50 μg; Type: EXPERIMENTAL; Interventions: Drug: indacaterol/glycopyrrolate | Arm Label: indacaterol 600 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: indacaterol | Arm Label: indacaterol 300 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: indacaterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: indacaterol/glycopyrrolate; Assigned to Arm(s): indacaterol/glycopyrrolate 300/50 μg | Intervention Type: DRUG; Name: indacaterol; Assigned to Arm(s): indacaterol 300 μg, indacaterol 600 μg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium (QVA149), Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol, Drug: Placebo to indacaterol and glycopyrronium (QVA149) | Intervention Type: DRUG; Name: indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): fluticasone/salmeterol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparative Study of Three Airway Clearance Techniques With Different Autonomy Degrees in Non Cystic Fibrosis Bronchiectasis: Randomized Cross-over Trial.
Brief Summary: Study design: a randomized, crossover trial. Each patient performed three different airway clearance techniques (Autogenic drainage, slow expiratory with glottis opened in lateral posture \[ELTGOL\], temporary- positive expiratory pressure \[T-PEP\] with not similar autonomy degree in a randomized order. Each technique were applied in 3 sessions during one week at alternate days (Monday /Wednesday/Friday or Tuesday/Thursday/Saturday). The time spent in each bronchial session was 40 minutes. Seven days were the wash-out time period between the different techniques.


Options:
A: Arm Label: HFCWO; Type: EXPERIMENTAL; Interventions: Device: HFCWO - SmartVest | Arm Label: Placebo/Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: HFCWO - SmartVest; Assigned to Arm(s): HFCWO
B: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
C: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
D: Arm Label: Autogenic drainage; Type: ACTIVE_COMPARATOR; Interventions: Other: Autogenic drainage | Arm Label: Slow expiration with glottis opened in lateral posture; Type: ACTIVE_COMPARATOR; Interventions: Other: Slow expiration with glottis opened in lateral posture | Arm Label: Temporary-Positive Expiratory Pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Temporary-positive expiratory pressure | Intervention Type: OTHER; Name: Autogenic drainage; Assigned to Arm(s): Autogenic drainage | Intervention Type: OTHER; Name: Slow expiration with glottis opened in lateral posture; Assigned to Arm(s): Slow expiration with glottis opened in lateral posture | Intervention Type: OTHER; Name: Temporary-positive expiratory pressure; Assigned to Arm(s): Temporary-Positive Expiratory Pressure

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Hospital-based Intervention Using Motivational Interviewing and Interactive Voice Response to Reduce Readmissions in Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial
Brief Summary: The primary purpose of this study is to determine the effectiveness of a hospital-based intervention, using motivational interviewing and interactive voice response (IVR), to reduce hospital readmissions within 90 days of enrollment compared to usual care, for patients with heart failure and chronic obstructive pulmonary disease.


Options:
A: Arm Label: MI + IVR; Type: EXPERIMENTAL; Interventions: Behavioral: MI + IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + IVR; Assigned to Arm(s): MI + IVR
B: Arm Label: Coordinated discharge; Type: EXPERIMENTAL; Interventions: Other: Coordinated discharge | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Coordinated discharge; Assigned to Arm(s): Coordinated discharge | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: TCM integrated group; Type: ACTIVE_COMPARATOR; Interventions: Other: acupuncture, massage and basic TCM treatment | Arm Label: Western Medicine group; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation and WM basic treatment | Intervention Type: OTHER; Name: acupuncture, massage and basic TCM treatment; Assigned to Arm(s): TCM integrated group | Intervention Type: OTHER; Name: rehabilitation and WM basic treatment; Assigned to Arm(s): Western Medicine group
D: Arm Label: Discharge planning services; Type: ACTIVE_COMPARATOR; Interventions: Other: PACT-HF Model | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PACT-HF Model; Assigned to Arm(s): Discharge planning services

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Hospital-based Intervention Using Motivational Interviewing and Interactive Voice Response to Reduce Readmissions in Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial
Brief Summary: The primary purpose of this study is to determine the effectiveness of a hospital-based intervention, using motivational interviewing and interactive voice response (IVR), to reduce hospital readmissions within 90 days of enrollment compared to usual care, for patients with heart failure and chronic obstructive pulmonary disease.


Options:
A: Arm Label: Re-engineered hospital discharge; Type: EXPERIMENTAL; Interventions: Behavioral: Re-Engineered Hospital Discharge | Arm Label: Standard hospital discharge; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Re-Engineered Hospital Discharge; Assigned to Arm(s): Re-engineered hospital discharge
B: Arm Label: MI + IVR; Type: EXPERIMENTAL; Interventions: Behavioral: MI + IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + IVR; Assigned to Arm(s): MI + IVR
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: C-TraIn; Type: EXPERIMENTAL; Interventions: Other: Care Transitions Innovation (C-TraIn) | Intervention Type: OTHER; Name: Care Transitions Innovation (C-TraIn); Assigned to Arm(s): C-TraIn

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Clinical Pharmacist's Intervention in Management of Clinically Relevant Drug-drug Interactions in Patients With Chronic Heart Failure
Brief Summary: Drug-drug interactions (DDIs) are common in patients with chronic heart failure (CHF) and their incidence increases with the number of drugs that the patients are prescribed for treatment of their condition. Data bases often detect DDIs that are of high clinical relevance. The investigators have performed this study in order to detect clinically significant DDIs and to diminish their occurrence by sending notification about DDIs to attending physician.


Options:
A: Arm Label: Advice on DDIs; Type: EXPERIMENTAL; Interventions: Behavioral: Advice on DDIs | Arm Label: General advice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Advice on DDIs; Assigned to Arm(s): Advice on DDIs
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Early Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
C: Arm Label: CARE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter Reminder and Evaluation Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Catheter Reminder and Evaluation Program; Assigned to Arm(s): CARE
D: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Clinical Pharmacist's Intervention in Management of Clinically Relevant Drug-drug Interactions in Patients With Chronic Heart Failure
Brief Summary: Drug-drug interactions (DDIs) are common in patients with chronic heart failure (CHF) and their incidence increases with the number of drugs that the patients are prescribed for treatment of their condition. Data bases often detect DDIs that are of high clinical relevance. The investigators have performed this study in order to detect clinically significant DDIs and to diminish their occurrence by sending notification about DDIs to attending physician.


Options:
A: Arm Label: NMS; Type: EXPERIMENTAL; Interventions: Other: New Medicine Service | Arm Label: Current Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New Medicine Service; Assigned to Arm(s): NMS
B: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Advice on DDIs; Type: EXPERIMENTAL; Interventions: Behavioral: Advice on DDIs | Arm Label: General advice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Advice on DDIs; Assigned to Arm(s): Advice on DDIs

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pasos Saludables: A Pilot Intervention to Prevent Obesity and Diabetes Among Latino Farm Workers
Brief Summary: This is a study to assess the effectiveness of a culturally appropriate behavioral intervention to reduce obesity levels and ultimately the risk of developing diabetes type II in immigrant Latino farm workers. Workers enrolled in a 2:1 ratio by random allocation into an intervention or control arm of the study. The intervention participants received weekly classes for 10 weeks with education on diabetes, diet and physical activity and practical exercises. Both control and intervention were measured for weight, waist circumference, fasting blood glucose and interviewed before and after the study intervention. The main hypothesis was that intervention, but not control participants, would experience reduction in body measurements after the intervention.


Options:
A: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Behavioral Intervention; Assigned to Arm(s): Behavioral intervention, Control
B: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care
C: Arm Label: Behavioral Activation Treatment for Depression; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for Depression Treatment | Arm Label: Supportive Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Counseling | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for Depression Treatment; Assigned to Arm(s): Behavioral Activation Treatment for Depression | Intervention Type: BEHAVIORAL; Name: Supportive Counseling; Assigned to Arm(s): Supportive Counseling
D: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention

Answer: A